FuturHealth, a leader in personalized health and weight-loss care, announced the expansion of its wellness program to include the Wegovy pill. Through its comprehensive 360-degree platform, FuturHealth’s affiliated clinical providers can now prescribe the oral therapy to eligible members nationwide, following individualized clinical evaluation and exclusion criteria.
Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India
The program, priced at $198 per month, combines the Wegovy pill with ongoing medical oversight, access to Apple Fitness+, and the option to add a tailored GLP-1 meal plan designed by professional dietitians. Providers assess each patient on a case-by-case basis, ensuring a safe and effective transition for members moving from injectable therapies to oral options.
Dr. Michael Snyder, FuturHealth’s in-house obesity specialist, explained that the Wegovy pill represents a major advancement in obesity treatment, noting that it has shown average weight-loss results of about 17 percent when paired with lifestyle modifications. He emphasized that combining oral therapy with clinical supervision and nutritional guidance allows more individuals to follow sustainable and personalized weight-management pathways.
Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk
FuturHealth’s care and support teams assist members throughout the treatment transition, including clinical visits to determine eligibility and proper titration, ensuring seamless continuity of care.
Luke Mahoney, co-founder and CEO of FuturHealth, highlighted that the program has already helped hundreds of thousands of members achieve significant health improvements. He described the addition of the Wegovy pill as a breakthrough, providing the most affordable FDA-approved GLP-1 option while offering flexible and convenient care. Mahoney added that combining medication with FuturHealth’s proven support and personalized wellness solutions maximizes results and expands access to long-term health improvements.
The introduction of the Wegovy pill reinforces FuturHealth’s commitment to personalized health. Alongside GLP-1 medications, the platform remains a pioneer in offering customized meal programs, and evidence shows that members benefit more from the integrated approach than from medication alone.
Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
